Esperion Therapeutics, Inc.

Contributing Author

Recent Articles by Esperion Therapeutics, Inc.

Oct-27	Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025 ESPR +7.01% GlobeNewswire
Oct-23	Esperion to Report Third Quarter 2025 Financial Results on November 6 ESPR GlobeNewswire
Oct-16	Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis ESPR GlobeNewswire
Oct-07	Esperion Announces Pricing of Public Offering of Common Stock ESPR GlobeNewswire
Oct-07	Esperion Announces Proposed Public Offering of Common Stock ESPR GlobeNewswire
Oct-03	Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Prior to April 19, 2040 ESPR GlobeNewswire
Sep-19	Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL in Japan for the Treatment of Hypercholesterolemia ESPR GlobeNewswire
Aug-29	Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias ESPR GlobeNewswire
Aug-26	Esperion to Participate in Upcoming September Investor Conferences ESPR GlobeNewswire
Aug-07	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ESPR GlobeNewswire
Aug-05	Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update ESPR GlobeNewswire
Jul-22	Esperion to Report Second Quarter 2025 Financial Results on August 5 ESPR GlobeNewswire
Jul-08	Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 ESPR GlobeNewswire
Jul-01	Esperion Appoints Craig Thompson to Board of Directors ESPR GlobeNewswire
Jun-02	Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 ESPR GlobeNewswire
May-20	Esperion to Participate in Upcoming June Investor Conferences ESPR GlobeNewswire
May-12	Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 ESPR GlobeNewswire
May-09	Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference ESPR GlobeNewswire
May-08	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ESPR GlobeNewswire
May-08	Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Canada ESPR GlobeNewswire
May-06	Esperion Reports First Quarter 2025 Financial Results ESPR GlobeNewswire

Esperion Therapeutics, Inc.

Recent Articles by Esperion Therapeutics, Inc.

Upgrade your FINVIZ experience